These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
330 related articles for article (PubMed ID: 22419236)
1. Dermatan sulfate: an alternative to unfractionated heparin for anticoagulation in hemodialysis patients. Vitale C; Berutti S; Bagnis C; Soragna G; Gabella P; Fruttero C; Marangella M J Nephrol; 2013; 26(1):158-63. PubMed ID: 22419236 [TBL] [Abstract][Full Text] [Related]
2. Effects of dermatan sulfate for anticoagulation in continuous renal replacement therapy. Vitale C; Verdecchia C; Bagnis C; Ganzaroli M; Giorcelli G; Marangella M J Nephrol; 2008; 21(2):205-12. PubMed ID: 18446715 [TBL] [Abstract][Full Text] [Related]
3. Discordant aPTT and anti-Xa values and outcomes in hospitalized patients treated with intravenous unfractionated heparin. Price EA; Jin J; Nguyen HM; Krishnan G; Bowen R; Zehnder JL Ann Pharmacother; 2013 Feb; 47(2):151-8. PubMed ID: 23386070 [TBL] [Abstract][Full Text] [Related]
4. Activated partial thromboplastin time versus antifactor Xa heparin assay in monitoring unfractionated heparin by continuous intravenous infusion. Guervil DJ; Rosenberg AF; Winterstein AG; Harris NS; Johns TE; Zumberg MS Ann Pharmacother; 2011 Jul; 45(7-8):861-8. PubMed ID: 21712506 [TBL] [Abstract][Full Text] [Related]
5. Anticoagulant efficacy of PEG-Hirudin in patients on maintenance hemodialysis. Pöschel KA; Bucha E; Esslinger HU; Ulbricht K; Nörtersheuser P; Stein G; Nowak G Kidney Int; 2004 Feb; 65(2):666-74. PubMed ID: 14717940 [TBL] [Abstract][Full Text] [Related]
6. Higher Maximum Doses and Infusion Rates Compared with Standard Unfractionated Heparin Therapy Are Associated with Adequate Anticoagulation without Increased Bleeding in Both Obese and Nonobese Patients with Cardiovascular Indications. Floroff CK; Palm NM; Steinberg DH; Powers ER; Wiggins BS Pharmacotherapy; 2017 Apr; 37(4):393-400. PubMed ID: 28107569 [TBL] [Abstract][Full Text] [Related]
7. A comparative trial of anti-factor Xa levels versus the activated partial thromboplastin time for heparin monitoring. Vandiver JW; Vondracek TG Hosp Pract (1995); 2013 Apr; 41(2):16-24. PubMed ID: 23545756 [TBL] [Abstract][Full Text] [Related]
8. Effectiveness of a Calculation-Free Weight-Based Unfractionated Heparin Nomogram With Anti-Xa Level Monitoring Compared With Activated Partial Thromboplastin Time. Kindelin NM; Anthes AM; Providence SM; Zhao X; Aspinall SL Ann Pharmacother; 2021 May; 55(5):575-583. PubMed ID: 32964730 [TBL] [Abstract][Full Text] [Related]
9. Thrombin formation and effect of unfractionated heparin during pediatric cardiac catheterization. Chen D; Långström S; Petäjä J; Heikinheimo M; Pihkala J Catheter Cardiovasc Interv; 2013 Jun; 81(7):1174-9. PubMed ID: 22915548 [TBL] [Abstract][Full Text] [Related]
11. The PiCT Brisset AC; Ferrández A; Krause M; Rathbun S; Marlar R; Korte W J Thromb Haemost; 2016 Nov; 14(11):2187-2193. PubMed ID: 27582411 [TBL] [Abstract][Full Text] [Related]
12. Antithrombotic properties of dermatan sulphate (MF 701) in haemodialysis for chronic renal failure. Ryan KE; Lane DA; Flynn A; Ireland H; Boisclair M; Shepperd J; Curtis JR Thromb Haemost; 1992 Nov; 68(5):563-9. PubMed ID: 1455403 [TBL] [Abstract][Full Text] [Related]
13. Evaluation of weight-based dosing of unfractionated heparin in obese children. Taylor BN; Bork SJ; Kim S; Moffett BS; Yee DL J Pediatr; 2013 Jul; 163(1):150-3. PubMed ID: 23414664 [TBL] [Abstract][Full Text] [Related]
14. Partial thromboplastin time is more predictive of bleeding than anti-Xa levels in heparinized pediatric patients after cardiac surgery. Oladunjoye OO; Sleeper LA; Nair AG; Trenor CC; VanderPluym C; Kheir JN; Emani SM J Thorac Cardiovasc Surg; 2018 Jul; 156(1):332-340.e1. PubMed ID: 29709361 [TBL] [Abstract][Full Text] [Related]
15. Delayed efficient anticoagulation with heparin in patients with a weight of 110 kg and more treated for acute coronary syndrome. Joncas SX; Poirier P; Ardilouze JL; Carrier N; Fayad T; Farand P Obesity (Silver Spring); 2013 Sep; 21(9):1753-8. PubMed ID: 23404940 [TBL] [Abstract][Full Text] [Related]
16. Antifactor Xa levels versus activated partial thromboplastin time for monitoring unfractionated heparin. Vandiver JW; Vondracek TG Pharmacotherapy; 2012 Jun; 32(6):546-58. PubMed ID: 22531940 [TBL] [Abstract][Full Text] [Related]
17. The safety of heparins in end-stage renal disease. Sonawane S; Kasbekar N; Berns JS Semin Dial; 2006; 19(4):305-10. PubMed ID: 16893408 [TBL] [Abstract][Full Text] [Related]
18. [The impact of heparin bolus from dysfunctional lumen of dual lumen central venous catheter on activated partial thromboplastin time during hemodialysis: is additional heparinization necessary?]. Sefer S; Kes P; Raić B; Heinrich B; Degoricija V; Szavits-Nossan J Acta Med Croatica; 2006 Jun; 60(3):281-5. PubMed ID: 16933844 [TBL] [Abstract][Full Text] [Related]
19. Predictors of initial nontherapeutic anticoagulation with unfractionated heparin in ST-segment elevation myocardial infarction. Cheng S; Morrow DA; Sloan S; Antman EM; Sabatine MS Circulation; 2009 Mar; 119(9):1195-202. PubMed ID: 19237657 [TBL] [Abstract][Full Text] [Related]
20. Comparison of Managing Factor Xa Inhibitor to Unfractionated Heparin Transitions by aPTT Versus a Treatment Guideline Utilizing Heparin Anti-Xa Levels. Dingus SJ; Smith AR; Dager WE; Zochert S; Nothdurft SA; Gulseth MP Ann Pharmacother; 2022 Dec; 56(12):1289-1298. PubMed ID: 35499336 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]